Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
Date:5/8/2012

al cancer, we remain excited by the prospects of the Zerenex opportunity as a treatment for hyperphosphatemia.  Following two successful short-term Phase 3 studies of Zerenex, in the U.S. and Japan, we look forward to the completion of the Phase 3 clinical programs in the U.S. and Japan by year-end, and the potential New Drug Application filings in the U.S., Europe and Japan within less than  twelve months."  Ron Bentsur, continued, "Our financial position remains strong and we believe that we have sufficient capital to take us beyond the anticipated NDA filings for Zerenex."

The Company will host an investor conference call tomorrow, Wednesday, May 9, 2012, at 8:30am EDT, to discuss the Company's first quarter financial results and provide a business outlook for the remainder of 2012.In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Encision Inc. (OTCQB:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 2014. The Company posted quarterly net revenue ... $414 thousand, or $(0.04) per share. These results compare ... loss of $50 thousand, or $(0.01) per share, in ...
(Date:10/31/2014)... , Oct. 30, 2014 Electronic ... electronic transmission of prescription related information between ... system allows a physician and nurse practitioner ... a medication error occurs during pharmacy operations. ... applications. It provides complete medical lists, conducts ...
(Date:10/30/2014)... , Oct. 30, 2014  Misonix, Inc. (NASDAQ: ... company that designs, manufactures and markets innovative therapeutic ultrasonic ... announced today that it will report financial results for ... 6, 2014. The Company has scheduled a conference call ... pm ET to review the results. ...
Breaking Medicine Technology:Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5E-Prescribing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2
... Resources, one of the world,s leading research and ... that, in 2008, human epidermal growth factor receptor ... Herceptin and GlaxoSmithKline/Nippon Kayaku,s Tykerb/Tyverb -- were the ... uptake of Herceptin and Tykerb/Tyverb and the expected ...
... -- Chindex International, Inc.,("Chindex") (Nasdaq: CHDX ), a leading independent ... of China, today,announced results for the second quarter and first half ... Financial Highlights:, -- Revenue in the second ... a year over year basis;, ...
Cached Medicine Technology:Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018 2Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 2Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 4Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 5Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 6Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 7Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 8Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 9Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 10Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 11
(Date:10/31/2014)... 2014 Radiology and EMR Integration ... difference between diagnostic imaging centers but Connectivity is ... DigitalOne. “Differentiation is critical in all businesses ... you consider the intense competition and the downward ... will stand-out from the competition by fully integrating ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Carving pumpkins and ... send many children to emergency rooms in the United ... holidays, Halloween had the fifth highest number of ER ... to 2007-2013 data from the National Electronic Injury Surveillance ... involved the head, noted the American Academy of Orthopaedic ...
(Date:10/31/2014)... of Health will facilitate communication among scientists, clinicians, ... from diagnosis to treatment. The Research Domain Criteria ... Institute of Mental Health (NIMH), part of NIH, ... initiative. , The aim of the RDoC ... that translates basic science into clinical settings by ...
(Date:10/31/2014)... News) -- A comparison of two of the most ... gastric bypass helped patients shed more excess pounds than ... short-term complications and long-term hospitalizations. Gastric-bypass surgery makes ... your body does not absorb all the calories from ... Health. Gastric banding is a type of weight-loss procedure ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, 2014 (HealthDay ... of broken bones and injured joints, a new study reports. ... percent of people who had an eczema flare-up in the past ... percent had an injury that caused a limitation of function. ... had more than double the risk of having had a fracture ...
Breaking Medicine News(10 mins):Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2Health News:Halloween at the ER Is No Treat 2Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2
... Jan. 13 (HealthDay News) -- Two extra steps may improve ... , A Pap smear is the standard test, but findings ... of the National Cancer Institute call for patients to ... after the Pap smear if they have HPV infections. , ...
... shows value of exercise in treating peripheral arterial disease , , ... that a planned program of walking is good for people ... should check the results of a new U.S. government-funded study. ... of whom didn,t have the pain that is the classic ...
... suggests , , TUESDAY, Jan. 13 (HealthDay News) -- Women calling ... to the hospital after an emergency medical services team had ... , It,s not clear why this was the case, but ... heart attacks. In particular, differences in initial symptoms could explain ...
... National Alliance for Caregiving Call on the New Congress ... CaregiversSAN MATEO, Calif., Jan. 13 There are more ... family members and loved ones: an aging or ailing ... spouse with Alzheimer,s, a sibling with a traumatic war ...
... from White,women on a range of worries about workplace, education and ... decade cited by greater,proportions of Black women than White women include: ... (84 % vs. 68 %), -- Unequal pay ... (72% vs. 57%), -- Limited opportunities for job ...
... S&R Communications Group has entered,a strategic partnership with ... for chorea associated with Huntington,s,disease (HD). Xenazine is ... any HD-related symptom. , ... to help Ovation launch,Xenazine," said S&R President Paul ...
Cached Medicine News:Health News:Walking Is Good for Blocked Leg Arteries 2Health News:Women With Heart Attack Symptoms See Delays in Care 2Health News:Women With Heart Attack Symptoms See Delays in Care 3Health News:Caregivers Need a Bailout Too! (or 1% for Families) 2Health News:Caregivers Need a Bailout Too! (or 1% for Families) 3Health News:Caregivers Need a Bailout Too! (or 1% for Families) 4Health News:Caregivers Need a Bailout Too! (or 1% for Families) 5Health News:Caregivers Need a Bailout Too! (or 1% for Families) 6Health News:YWCA Survey Shows Greater Economic Concerns Among Black Women Than White Women 2
... BchiVac V-500 with Vacuum Controller V-800 and water-cooled ... from Model V-500 is a ... most vacuum applications. Applications Ideally ... evaporators Laboratory vacuum source for instruments ...
... Combines BchiVac V-500 with Vacuum Controller V-800 ... Electronic switching mechanism turns V-500 on and off as ... Model V-500 is a powerful PTFE membrane vacuum pump ... Ideally suited for use with up to two ...
... Combines BchiVac V-500 and water-cooled secondary condenser ... is a powerful PTFE membrane vacuum pump ... Applications Ideally suited for use ... Laboratory vacuum source for instruments including ...
... The Universal Vacuum System UVS400 is a ... The UVS400 combines a refrigerated vapor trap ... a single integrated unit. The easy-to-use, wide-mouth ... solvent into single jar for easy disposal. ...
Medicine Products: